Literature DB >> 17698758

Clinical and genetic heterogeneity in multifocal vitelliform dystrophy.

Camiel J F Boon1, B Jeroen Klevering, Anneke I den Hollander, Marijke N Zonneveld, Thomas Theelen, Frans P M Cremers, Carel B Hoyng.   

Abstract

OBJECTIVE: To describe the clinical and genetic findings in 15 patients with multifocal vitelliform lesions.
METHODS: All patients and, if possible, affected family members underwent an ophthalmic examination and their genomic DNA was analyzed for mutations in the vitelliform macular dystrophy 2 (VMD2) gene. Patients who did not have a mutation in the VMD2 gene were screened for mutations in the peripherin/RDS gene.
RESULTS: Patient age at onset of the disease was highly variable, ranging from 5 to 59 years. The peripheral lesions varied in number, size, and overall appearance but showed similar characteristics at autofluorescence imaging and optical coherence tomography compared with the central vitelliform lesion. Mutations in the VMD2 gene were identified in 9 of 15 patients. One patient without a VMD2 mutation carried a sequence variant in the 5' untranslated region of the peripherin/RDS gene.
CONCLUSIONS: Multifocal vitelliform dystrophy is a clinically and genetically heterogeneous retinal disease that can be caused by mutations in the VMD2 gene. Other genes associated with this phenotype remain to be identified. CLINICAL RELEVANCE: Clinical and molecular genetic characterization of multifocal vitelliform dystrophy may lead to better understanding of the pathophysiological mechanisms underlying this phenotype and may enable a more accurate prognosis in individual patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698758     DOI: 10.1001/archopht.125.8.1100

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  30 in total

1.  Clinical utility gene card for: BEST1-related dystrophies (Bestrophinopathies).

Authors:  Simon C Ramsden; Alice E Davidson; Bart P Leroy; Anthony T Moore; Andrew R Webster; Graeme C M Black; Forbes D C Manson
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

2.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

3.  Molecular consequences of BEST1 gene mutations in canine multifocal retinopathy predict functional implications for human bestrophinopathies.

Authors:  Karina E Guziewicz; Julianna Slavik; Sarah J P Lindauer; Gustavo D Aguirre; Barbara Zangerl
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-23       Impact factor: 4.799

Review 4.  [Genetic diseases of the retinal pigment epithelium].

Authors:  M N Preising; B Lorenz
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

5.  [Fundus autofluorescence in patients with inherited retinal diseases : patterns of fluorescence at two different wavelengths].

Authors:  T Theelen; C J F Boon; B J Klevering; C B Hoyng
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

6.  Quantitative fundus autofluorescence and optical coherence tomography in best vitelliform macular dystrophy.

Authors:  Tobias Duncker; Jonathan P Greenberg; Rithambara Ramachandran; Donald C Hood; R Theodore Smith; Tatsuo Hirose; Russell L Woods; Stephen H Tsang; François C Delori; Janet R Sparrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-13       Impact factor: 4.799

7.  Pathogenicity of new BEST1 variants identified in Italian patients with best vitelliform macular dystrophy assessed by computational structural biology.

Authors:  Vladimir Frecer; Giancarlo Iarossi; Anna Paola Salvetti; Paolo Enrico Maltese; Giulia Delledonne; Marta Oldani; Giovanni Staurenghi; Benedetto Falsini; Angelo Maria Minnella; Lucia Ziccardi; Adriano Magli; Leonardo Colombo; Fabiana D'Esposito; Jan Miertus; Francesco Viola; Marcella Attanasio; Emilia Maggio; Matteo Bertelli
Journal:  J Transl Med       Date:  2019-10-01       Impact factor: 5.531

Review 8.  Functional roles of bestrophins in ocular epithelia.

Authors:  Alan D Marmorstein; Harold E Cross; Neal S Peachey
Journal:  Prog Retin Eye Res       Date:  2009-05-04       Impact factor: 21.198

Review 9.  Gene therapy for PRPH2-associated ocular disease: challenges and prospects.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-28       Impact factor: 6.915

10.  Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene.

Authors:  Giuseppe Querques; Jennyfer Zerbib; Rossana Santacroce; Maurizio Margaglione; Nathalie Delphin; Jean-Michel Rozet; Josseline Kaplan; Domenico Martinelli; Nicola Delle Noci; Gisèle Soubrane; Eric H Souied
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.